Goldman Sachs
PRME icon

Goldman Sachs’s Prime Medicine PRME Stock Holding History

Goldman Sachs’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Buy
3,430,518
+2,460,093
+254% +$8.17M ﹤0.01% 3056
2026
Q1 		$3.38M Sell
970,425
-785,343
-45% -$2.99M ﹤0.01% 4072
2025
Q4 		$6.09M Buy
1,755,768
+1,345,032
+327% +$5.98M ﹤0.01% 3561
2025
Q3 		$2.28M Buy
410,736
+203,728
+98% +$828K ﹤0.01% 4360
2025
Q2 		$511K Sell
207,008
-44,391
-18% -$68.4K ﹤0.01% 5146
2025
Q1 		$500K Sell
251,399
-170,499
-40% -$435K ﹤0.01% 5180
2024
Q4 		$1.23M Buy
421,898
+201,754
+92% +$708K ﹤0.01% 4667
2024
Q3 		$852K Buy
220,144
+140,777
+177% +$652K ﹤0.01% 4747
2024
Q2 		$408K Buy
79,367
+41,187
+108% +$250K ﹤0.01% 4932
2024
Q1 		$267K Sell
38,180
-12,969
-25% -$98.4K ﹤0.01% 5018
2023
Q4 		$453K Sell
51,149
-7,762
-13% -$59.8K ﹤0.01% 4816
2023
Q3 		$562K Buy
+58,911
New +$765K ﹤0.01% 4606

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's PRME Position: Q2 2026 in Review

Goldman Sachs increased its Prime Medicine (PRME) stake by 254% in Q2 2026, buying an estimated $8.17M and bringing the position to 3,430,518 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

Goldman Sachs first reported a position in PRME in Q3 2023 and has held it in 12 quarters since. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Goldman Sachs held 3,430,518 shares of Prime Medicine worth $12.7M as of Q2 2026.
  • Goldman Sachs bought 2,460,093 Prime Medicine shares in Q2 2026, an estimated $8.17M.
  • Prime Medicine made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3056 holding.
  • Goldman Sachs first reported a position in Prime Medicine in Q3 2023 and has held it in 12 quarters since.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.